• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KTRA

    Kintara Therapeutics Inc.

    Subscribe to $KTRA
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.

    IPO Year:

    Exchange: NASDAQ

    Website: kintara.com

    Recent Analyst Ratings for Kintara Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/20/2022$6.00 → $3.00Buy
    HC Wainwright & Co.
    9/30/2021$7.00 → $5.00Buy
    Aegis Capital
    9/28/2021$6.00Buy
    HC Wainwright & Co.
    See more ratings

    Kintara Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 9:12:33 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:50:14 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ng George K

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:47:13 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Ng George K claimed no ownership of stock in the company (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:44:01 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director List Alan

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:41:46 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider List Alan claimed no ownership of stock in the company (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:38:51 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Manuso James S J

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:36:17 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Manuso James S J claimed no ownership of stock in the company (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:33:41 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Yamashita Dennis claimed no ownership of stock in the company (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:13:22 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bianco James A. was granted 2,323,307 shares (SEC Form 4)

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:10:14 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kintara Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously

      1/20/22 5:37:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

      Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      9/30/21 9:44:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00

      9/28/21 6:18:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

      Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $7.00 from $6.00 previously

      2/3/21 11:31:49 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care